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Abstract 
Introduction 
We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer 
in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from 
diagnosis and beyond 40 years of age among all survivors. 
Methods 
This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before 
age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted 
relative risks and relative excess risks were calculated. All statistical tests were two-sided. 
Results 
Overall, survivors were 21.65 times (95% confidence interval = 18.97 to 24.60 times) more likely to 
be diagnosed with a subsequent primary bone cancer than expected from the general population. 
The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, 
and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since 
diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there 
were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 
30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of 
retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. 
Conclusions 
For all survivors combined and the cancer groups with the greatest excess number of bone cancers, 
the excess numbers observed declined with both age and years from diagnosis. These results 
provide novel, reliable, and unbiased information about risks and risk factors among long-term 
survivors of childhood and adolescent cancer. 
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Issue Section: 
Survival after childhood and adolescent cancer has improved substantially, with approximately 80% 
of those diagnosed surviving at least five years (1). As a result, there are now an estimated 300 000 
to 500 000 survivors of childhood and adolescent cancer in Europe (2). However, increased survival 
comes at a cost because the treatments utilized to achieve such successful survival rates are also 
associated with adverse health outcomes. One of the most serious such outcomes concerns 
subsequent primary neoplasms (SPNs), with reports on cancer-related or treatment-induced SPNs 
first being published in the 1970s (3). Since then, numerous studies have demonstrated that there 
are substantially higher risks of SPNs among the overall population of childhood and adolescent 
cancer survivors compared with that expected from the general population (4–9), with risks ranging 
from three- to sixfold that expected (4–12). In particular, when assessed by the SPN site, several 
reports have indicated that, of all SPNs, subsequent primary bone cancers have the greatest 
multiplicative excess risk (5,6), ranging from 10-fold to 45-fold that expected (4–6,8,13,14). 
However, the previous literature has generally been limited by a small number of bone SPNs, and 
apart from European cohorts based on patients diagnosed before 1970 in France (14), the Nordic 
countries (4), and the United Kingdom (5), the interval of follow-up from diagnosis has been 
limited in other previous studies. 
Thus, we sought to understand the risks of bone SPNs, both overall and for specific morphological 
subtypes, using the PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up 
Studies (PanCareSurFup), the largest cohort of childhood and adolescent cancer survivors currently 
available. With nearly 70 000 five-year survivors of cancer diagnosed before the age of 20 and 235 
observed bone SPNs, the latter being 2.5 times more than in the largest previous report (5), the 
PanCareSurFup SPN cohort gives an unrivaled opportunity to assess the long-term risks of bone 
SPNs. In particular, our aims for this study were to determine the risks and risk factors for bone 
SPNs in this Europe-wide cohort and, in particular, to assess the risks among survivors followed 
beyond 40 years from diagnosis or to attained ages beyond 40 years. 
Methods 
PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies 
PanCareSurFup (15) is a pan-European project within the larger PanCare initiative (16) that seeks to 
better understand the frequency, severity, and impact of late effects of childhood and adolescent 
cancer. For this study, 13 population-based and hospital-based cohorts of childhood and adolescent 
cancer survivors from the following 12 European countries were pooled to assess the risk of bone 
SPNs: Denmark, Finland, France, Hungary, Iceland, Italy, the Netherlands, Norway, Slovenia, 
Sweden, Switzerland, and the United Kingdom. Ethical approval was obtained separately within 
each participating country, observing all relevant national laws and requirements. The larger 
European cohorts relating to specific countries included here have been described in detail in a 
separate publication, together with an overview of PanCareSurFup (17). 
Cohort Ascertainment 
All childhood and adolescent diagnoses within each of the 13 participating cohorts were pooled (n = 
105 015). In order to classify the first primary neoplasms (FPNs) of each survivor according to the 
International Classification of Childhood Tumors (ICCC), third edition (18), all first primary 
neoplasms (FPNs) were coded using the third revision of the International Classification of Disease 
Oncology (ICD-O) with the aid of the International Agency for Research on Cancer 
(IARC)/International Association of Cancer Registries Check and Conversion Program (19). As 
only typography data were available for Slovenian diagnoses before 1983, these survivors could not 
be classified according to the ICCC (typography and morphology required); these individuals were 
not excluded from the study, but rather grouped into a “not classifiable” FPN type. All remaining 
diagnoses that did not conform to the ICCC were excluded. Furthermore, FPN diagnoses that did 
not have a malignant behavior were excluded, except for intracranial tumors where benign and 
unspecified behaviors were included. To ensure consistency between cohorts, survivors diagnosed 
with Langerhans cell histiocytosis, myelodysplastic syndromes, chronic myeloproliferative, 
lymphoproliferative disorders, or immunoproliferative diseases were excluded. Finally, only those 
surviving at least five years after an initial diagnosis before age 20 years were included. Ultimately, 
69 460 five-year survivors of childhood and adolescent cancer, diagnosed between 1940 and 2008, 
were included in this study (Supplementary Figure 1, available online). 
Subsequent Primary Neoplasm Ascertainment 
The ascertainment method for SPNs varied by country (Supplementary Table 1, available online), 
but the following sources were utilized: population-based cancer registries, late effect clinics, 
questionnaires, medical records and hospital data, national mortality records, and health insurance 
registries. Validation of all SPNs was undertaken principally using pathology reports, although 
occasionally other definitive diagnostic reports were used. To be included, SPNs had to be 
histologically different from the FPN and have a malignant behavior code. For this study, all bone 
SPNs occurred in a bone site and were classified according to the following morphological groups: 
osteosarcoma, chondrosarcoma, Ewing sarcoma, and all other bone SPNs (Supplementary Table 2, 
available online). 
General Population Cancer Rates 
General population cancer rates were obtained from the IARC’s Cancer Incidence in Five 
Continents Time Trends (20). Country-specific rates for bone cancer overall were available for all 
countries, except Hungary. Morphology-specific bone cancer rates were available for all countries, 
except Hungary, Slovenia, Sweden, Norway, and Finland. To estimate missing rates, we utilized the 
Italian general population rates for Hungary and Slovenia and Danish general population rates for 
Finland, Norway, and Sweden; Italy and Denmark were selected due to their relatively close 
geographical proximity to the corresponding countries with missing general population data. If the 
range of calendar years for the general population rates did not cover the ascertainment period of 
the SPNs for a country, rates from the closest available year were used. 
Statistical Analyses 
Follow-up for a bone SPN began five years after the FPN diagnosis date and ended at the first 
occurrence of loss to follow-up, death, or the study exit date (Supplementary Table 1, available 
online). Standardized incidence ratios were calculated as the observed divided by the expected 
number of bone cancers. Absolute excess risks per 10 000 person-years were calculated as the 
observed minus the expected number of bone cancers, divided by person-years at risk and 
multiplied by 10 000. For both the standardized incidence ratio and absolute excess risk calculations, 
multiple SPNs were included to avoid bias. We concentrate on absolute excess risks rather than 
standardized incidence ratios because of their direct and clear interpretation as the excess numbers 
of SPNs beyond that expected per 10 000 person-years. The expected number of bone cancers was 
calculated by multiplying the person-years for each sex-, age (five-year)-, and calendar year (one-
year)–specific stratum by the corresponding general population cancer rate and then summing 
across the strata. Using multivariable Poisson regression models, we also provide relative risks 
(RRs) and relative excess risks (RERs), which can be interpreted as the ratios of standardized 
incidence ratios and absolute excess risks, respectively, with respect to a specified reference 
category having adjusted for all other explanatory factors included within the model. The following 
explanatory factors were adjusted for within the models: sex, cohort, FPN diagnosis, age at 
diagnosis, treatment era, and years since diagnosis or attained age; years since diagnosis and 
attained age were not included in the same model due to collinearity. Likelihood ratio tests were 
utilized to test for heterogeneity and linear trends. 
The cumulative probability of bone SPNs, in relation to years since diagnosis, was calculated 
including the first bone SPN only, where death was treated as a competing risk. All statistical 
analyses were conducted using Stata 13.1 (21), where the criterion for statistical significance was a 
two-sided P value of less than .05. 
Data Availability 
The data are not publicly available due to them containing semi-identifiable information that could 
compromise research participant privacy. Nonetheless, additional summary tables of count data or 
person-years are available from the corresponding author upon request. 
Results 
Study Characteristics 
Individuals in the cohort were followed-up for a total of 1 126 424 person-years. The median follow-
up time from FPN diagnosis was 21.4 years (range = 5.0–66.6 years), and the median attained age 
was 29.7 years (range = 5.0–79.4 years) at study exit. Among the 69 460 cancer survivors included 
in the cohort, 235 bone SPNs were observed among 230 survivors (Table 1). Bone SPNs were most 
frequently observed among survivors of retinoblastoma (73 SPNs), bone sarcoma (37 SPNs), and 
soft tissue sarcoma (STS) (37 SPNs), which when combined accounted for nearly two-thirds of all 
bone SPNs observed.  
Risks and Risk Factors of Bone SPNs Overall 
Overall, survivors were 21.65 times (95% CI = 18.97 to 24.60 times) more likely to experience a 
bone SPN than expected, which equated to 1.99 (95% CI = 1.72 to 2.26) excess bone cancers per 10 
000 person-years (Tables 2). When the risk of a bone SPN was assessed by FPN diagnosis, all 
diagnostic groups were found to have at least a fivefold increased risk compared with that expected 
(Table 3). Retinoblastoma survivors were found to have the greatest excess risks both in 
multiplicative and absolute terms, with a standardized incidence ratio of 134.91 (95% CI = 105.74 
to 169.62) and 12.03 (95% CI = 9.25 to 14.81) excess bone cancers per 10 000 person-years. Bone 
sarcoma and STS survivors had the next greatest excess risks at 78.18-fold (95% CI = 55.04 to 
107.75) and 46.77-fold (95% CI = 32.93 to 64.47) that expected, respectively. After all FPNs 
combined, there was not a statistically significant linear trend in excess risks (RRs or RERs) of 
bone SPN with either age at diagnosis of FPN or treatment era of FPN when adjusted, but as years 
since diagnosis and attained age increased, both the relative risks and relative excess risks 
statistically significantly declined (all Ptrend < .001). Specifically, from the age range of five to 19 
years to 40+ years of age, the standardized incidence ratio declined from 28.98 (95% CI = 24.62 to 
33.88) to 6.96 (95% CI = 2.55 to 15.14). Beyond 40 years from diagnosis and age 40 years, there 
were at most 0.45 excess bone SPNs per 10 000 person-years. At 45 years since diagnosis, the 
cumulative incidence of a bone SPN was 0.6% compared with 0.03% of the expected (Figure 1A).  
 
 
Risks and Risk Factors of Bone SPNs by FPN 
As retinoblastoma, bone sarcoma, and STS survivors experienced the greatest risks of developing a 
bone SPN, these three groups were explored in more detail. When explanatory factors were 
assessed, male retinoblastoma survivors were found to have a statistically significantly greater 
absolute excess risk than female retinoblastoma survivors after adjustment for potential confounders 
(Pheterogeneity = .04) (Table 4); no statistically significant effects were observed for the sex of bone 
sarcoma or STS survivors. There was no evidence of a relationship between excess risks (RRs or 
RERs) for bone SPNs and age at diagnosis, after adjustment, for bone sarcoma or STS survivors; 
age at diagnosis was not assessed as a risk factor for retinoblastoma survivors as 95.3% of these 
survivors were diagnosed at zero to four years. There was also no evidence of an increasing or 
decreasing linear trend in the excess risks (RRs or RERs) for bone SPNs among survivors of 
retinoblastoma, bone sarcoma, or STS treated in more recent eras. For retinoblastoma, bone 
sarcoma, and STS survivors, as years since diagnosis and attained age increased, the RERs declined 
linearly (all Ptrend < .05). Beyond 30 years from diagnosis and age 30 years, there were at most 5.02 
excess bone cancers per 10 000 person-years among survivors of each of retinoblastoma, bone 
sarcoma, and STS. In Table 4, we also provide the excess numbers of bone SPNs after all FPNs 
except retinoblastoma, bone sarcoma, and STS. Overall, 0.85 (95% CI = 0.65 to 1.04) excess bone 
SPNs were experienced per 10 000 person-years. This excess number declined (all Ptrend < .05) 
linearly with increased years from diagnosis and attained age. When the cumulative probability was 
assessed by FPN type, the risk was greatest for retinoblastoma survivors, reaching 3.2% at 25 years 
from diagnosis, while the corresponding cumulative probabilities for bone sarcoma, STS, all other 
FPNs, and that expected from the general population were 1.4%, 0.9%, 0.2%, and 0.02%, 
respectively (Figure 1B).  
Risks and Risk Factors of Morphology-Specific Bone SPNs 
When assessed by morphological subtype, 179 osteosarcoma, 14 Ewing sarcoma, 21 
chondrosarcoma, and 21 other bone SPNs were observed (Table 2); the corresponding standardized 
incidence ratios were 41.37 (95% CI = 35.53 to 47.90), 5.71 (95% CI = 3.12 to 9.58), 11.39 (95% CI 
= 7.05 to 17.41), and 9.37 (95% CI = 5.80 to 14.32). At 30 years from the FPN diagnosis, the 
cumulative probabilities for osteosarcoma, chondrosarcoma, and other bone SPNs were 
approximately 70 times (0.3%), 40 times (0.04%), and 50 times (0.05%) that expected for each 
respective morphological subtype; the cumulative probability for Ewing sarcoma SPNs at 20 years 
was 20 times (0.02%) that expected (Figure 1C). 
As 76.2% of the bone SPNs observed were osteosarcomas, potential explanatory factors were 
investigated only for this group (Table 3). Although both standardized incidence ratios and absolute 
excess risks were generally numerically greater for osteosarcoma than for bone SPNs overall, the 
pattern of relationships with explanatory factors was very similar to those seen for bone SPNs 
overall. 
Discussion 
Our study is the largest ever to assess the risk of bone SPNs among childhood and adolescent 
cancer survivors, with 69 460 five-year survivors, 1 126 424 person-years at risk, and 235 observed 
bone SPNs. There were more than 100 000 and 30 000 person-years accrued among survivors 
beyond age 40 years and beyond 40 years from diagnosis, respectively, enabling satisfactory 
assessment of excess risks for these groups of survivors for the first time. Among all five-year 
survivors, as years from diagnosis and attained age increased, both multiplicative and absolute 
excess risks declined linearly; among those surviving beyond 40 years from diagnosis and beyond 
40 years of age, the excess number of bone cancers did not exceed 0.5 per 10 000 persons per year. 
After each of retinoblastoma, bone sarcoma, and STS, the excess number of bone cancers also 
declined linearly with both increased years from diagnosis and increased attained age; beyond 30 
years from diagnosis and age 30 years, there were at most five excess bone cancers observed per 10 
000 person-years for each FPN type. Finally, there was no evidence of a relationship between 
excess risks (RRs or RERs) for bone SPNs and either age at diagnosis or treatment era, after taking 
into account confounding. 
Overall, the risk of a bone SPN was 22 times that expected from the general population, which is 
consistent with previous studies (4–6,8,13). The risk of a bone SPN was observed to vary by 
morphological subtype, with the multiplicative excess risks ranging from six times that expected 
from the general population for Ewing sarcoma SPNs to 41 times that expected from the general 
population for osteosarcoma SPNs. 
Survivors of retinoblastoma, bone sarcoma, and STS were observed to have the greatest risks of a 
bone SPNs, with risks of 135, 78, and 47 times that expected, respectively; these results are 
consistent with previous reports (6,13,22–30). The large increased risk observed in retinoblastoma 
survivors likely corresponds to the fact that heritable retinoblastoma survivors develop bone SPNs, 
particularly osteosarcomas, at substantially greater frequencies than the general population due to a 
genetic predisposition (13,28,30), in addition to the increased risk resulting from radiotherapy and 
chemotherapy experienced by both heritable and nonheritable survivors. For bone sarcoma and STS 
survivors, exposure to radiation and chemotherapy, specifically alkylating agents, has been 
previously shown to increase the risk of bone SPNs (13,22,26,28). Previous reports have also found 
increased risks of bone SPNs among bone sarcoma and STS survivors independent of treatment, 
which suggests potential genetic predisposition as well (6,28). 
Previous studies have suggested that bone SPNs after childhood and adolescent cancer largely occur 
in the short term following the original cancer, but these reports were based on limited follow-up 
(10,22). Our findings indicate for the first time that the excess number of bone cancers decline with 
both years from diagnosis and attained age to beyond 40 years in each timescale. It is important to 
remember, however, that the current survivors living beyond 40 years from diagnosis or attaining 
ages beyond 40 years may not be representative of future survivors reaching these milestones. 
Therefore, the presented findings are only applicable to survivors who have at least 40 years since 
diagnosis or 40 years’ attained age at the time of the study, which largely comprises survivors of 
central nervous system neoplasms, Hodgkin lymphoma, retinoblastoma, and Wilms tumors. It will 
be important to reassess our findings with additional follow-up in order to determine whether the 
risks of bone SPNs remain low among more recently treated survivors reaching mature adulthood. 
Finally, the excess number of bone cancers observed did not vary with more recent treatment era 
after all cancers, retinoblastoma, bone sarcoma, or STS, whereas five-year survival has improved 
substantially over the recent treatment eras covered by our data. For example, in Britain, five-year 
survival after all childhood cancers diagnosed in 1966–1970 and 1996–2000 increased from 28% to 
77%; corresponding figures after retinoblastoma, bone sarcoma, and STS were 86% to 96%, 23% to 
64%, and 32% to 66%, respectively (31). As treatment intensity generally increased in order to 
achieve such substantial improvements in five-year survival over the treatment eras covered by our 
data, it is very reassuring that the excess numbers of bone SPNs have not increased following 
treatment from 1940–1969 to beyond 2000. 
A potential limitation of our study is the statistically significant heterogeneity in bone SPN risks 
between cohorts. The most likely explanation of this heterogeneity relates to different cumulative 
levels of exposure to radiation (from radiotherapy) and cytotoxic drugs carcinogenic to bone 
between countries, resulting from differences in treatment practices over time (32). Although we 
were not able to find evidence of this in the literature for the at-risk groups identified in this study, 
variations in British, German, and Nordic treatment regimens were clearly documented for acute 
myeloid leukemia patients (33–35), and thus our explanation seems plausible. As detailed treatment 
information was unavailable in this study, we were not able to investigate further this hypothesis 
within our data, nor calculate dose-response relationships between the risk of development of bone 
SPNs and cumulative doses of radiotherapy and chemotherapy. Also, information on cancer-
predisposing genetic conditions was lacking, and therefore it was not possible to stratify results by, 
for example, heritability status for retinoblastoma survivors. However, as we are undertaking nested 
case-control studies as a part of PanCareSurFup, we shall overcome each of these limitations in the 
future, particularly in regards to whether there is evidence of variation in dose responses between 
cohorts. 
This largest-ever investigation into the risk of bone SPNs after childhood and adolescent cancers 
has provided strong evidence that the excess number of bone SPNs observed after all childhood 
cancer, retinoblastoma, bone sarcomas, and STS declines linearly with both increased years since 
diagnosis and attained age. Beyond 40 years from diagnosis and age 40 years, there were at most 
0.45 excess bone SPNs among all survivors per 10 000 person-years at risk; beyond 30 years from 
diagnosis and age 30 years, there were at most 5.02 excess bone SPNs after each of retinoblastoma, 
bone sarcoma, and STS per 10 000 person-years at risk. Despite the substantial improvement in 
five-year survival after each of these cancer groups since 1940 and the associated more intensive 
treatment, the excess number of bone SPNs observed has not increased among survivors of more 
recent treatments. The evidence assembled in this study provides reliable and unbiased information 
about risks and risk factors among long-term survivors not previously available, which is likely to 
be helpful to both survivors and health care professionals. 
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